Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Degree and continuing education programmes for society - we are effective Call for the MAKE/SENSE PhD Programme 2026 Academy of Art and Design Basel FHNW, hgk_institutexperimentelledesignmedienkulturen Your tasks The Basel Academy of Art and Design FHNW,
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Cherchez-vous à piloter lexcellence technique ? Rejoignez cette organisation innovante ! Relevez ce défi stratégique dans le secteur haut de gamme et façonnez lavenir ! Notre partenaire est une entreprise spécialisée en solutions techniques haut de
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Your position The successful candidate will play a central role in the design, analysis, and interpretation of computational and single-cell biology projects, ensuring high methodological standards, reproducibility, and robust analytical workflows. Responsibilities include: Leading computational analyses